Melanotan II for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: Melanotan-2, Melanotan 2, MT-II, MT-2, MTII

Motivation

Melanotan II is a laboratory-made copy of a natural body signal that instructs skin cells to produce pigment. Injected under the skin, it darkens the skin without sunlight. The same signal is also read by brain circuits that govern appetite and sexual arousal, so a compound sold mainly as a tanning agent turns out to touch several systems at once.

It was created in the 1980s by university researchers who hoped that a protective tan produced without sun exposure could lower skin cancer rates. That work led to two approved medicines built on the same chemistry, but this particular compound was never brought to market. It moved instead into an unregulated online trade, where what a buyer receives in a vial is frequently not what the label claims.

This review examines what is actually known about Melanotan II: how it works in the body, the human evidence for skin darkening, sexual response and appetite, the harms that have been reported from nausea to changes in moles, and the practical questions of dose, sourcing and monitoring that surround an unapproved injectable compound.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Melanotan II

The article covers the peptide’s chemical structure, its receptor targets, the University of Arizona origin story and the documented adverse effects in a single reference entry. It is a useful orientation to the compound’s identity and regulatory status before moving to the primary literature.

Examine

No Examine article exists for Melanotan II. Examine’s coverage is built around dietary supplements and nutrition compounds; Melanotan II is an unapproved injectable drug candidate sold outside any supplement framework, and injectable pharmaceutical-class agents of this kind fall outside the site’s editorial scope.

ConsumerLab

No ConsumerLab article exists for Melanotan II. ConsumerLab tests and reviews commercially sold dietary supplements; Melanotan II is an unapproved injectable drug candidate distributed as a “research use only” chemical rather than a retail supplement, so it falls outside the products the organization tests.

Systematic Reviews

The following systematic reviews are the ones indexed on PubMed that formally include Melanotan II within their search and inclusion criteria.

Insights into Tanning Biology and Tanning Products - Resnick et al., 2026

This review followed the reporting standards of PRISMA (a published checklist that sets out how a systematic review must be conducted and reported) across 68 studies of sunless tanning agents, treating melanotan I and II as one of four agent classes alongside dihydroxyacetone (the active ingredient of self-tanning lotions), forskolin and carotenoids. It is the only systematic review that assesses Melanotan II in its actual use context — cosmetic tanning — and it records rhabdomyolysis (muscle breakdown that releases damaging proteins into the blood), renal infarction (sudden loss of blood supply to part of a kidney) and priapism (a prolonged, painful erection) among the documented harms of unregulated use.
The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options - Fani et al., 2014

This review screened 664 papers and retained 15 studies of melanocortin-4 receptor agonists including Melanotan II, concluding that almost all of the work was preclinical and that no effective clinical treatment had emerged for receptor-deficient obesity. It is the most rigorous available assessment of the appetite and body-weight claims made for this receptor family.
The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review - Brennan et al., 2017

Melanotan I and II were searched without date restriction as one of the drug classes in this 133-paper review of injectable appearance-enhancing drugs, which maps user profiles, sourcing, risk behaviours and health outcomes. It is the best available evidence on who actually uses this compound and under what conditions.

Mechanism of Action

Melanotan II is a synthetic cyclic seven-amino-acid peptide modelled on the active core of alpha-melanocyte-stimulating hormone (α-MSH, the body’s own pigment-signaling hormone), with the structure Ac-Nle⁴-cyclo[Asp⁵, D-Phe⁷, Lys¹⁰]-α-MSH(4–10)-NH₂. Closing the molecule into a ring with a lactam bridge makes it far more resistant to the enzymes that destroy the natural hormone within minutes, and far more potent at its targets.

Non-selective melanocortin receptor agonism. The melanocortin receptors are a family of five cell-surface switches (MC1R through MC5R) that read α-MSH and related signals. Melanotan II activates MC1R, MC3R, MC4R and MC5R, with negligible activity at MC2R (the receptor for the stress hormone ACTH, or adrenocorticotropic hormone). This lack of selectivity is the whole story of the compound: the same molecule that darkens skin also reaches appetite and arousal circuits, which is why its side effects are not incidental but built in.
Pigment production through MC1R. In melanocytes (the pigment-producing cells of the skin), MC1R activation raises intracellular cyclic AMP (a universal cellular messenger), which switches on the master pigment gene regulator MITF and in turn the enzyme tyrosinase. The result is increased synthesis of eumelanin, the dark, ultraviolet-absorbing pigment, without any ultraviolet exposure being required to start the process.
Central appetite and energy effects through MC3R and MC4R. In the hypothalamus, MC4R activation reduces food intake and raises sympathetic nervous system outflow. This is the same pathway exploited by the approved obesity drug setmelanotide, and it is why reduced appetite appears in the human trial records as a consistent effect rather than a curiosity.
Erectile and libido effects through central melanocortin receptors. Melanocortin signaling in the hypothalamic paraventricular nucleus and spinal cord recruits oxytocin- and dopamine-dependent pathways that initiate erection independently of any local vascular action in the penis. This distinguishes it from PDE5 inhibitors (phosphodiesterase type 5 inhibitors, the drug class that includes sildenafil), which act on blood vessels in the penis and require sexual stimulation to work.
Peripheral MC5R effects. MC5R is expressed in sebaceous and other exocrine glands, and its activation is the presumed basis of the increased oiliness and acne that users commonly describe.
Competing mechanistic accounts of skin cancer risk. Two mechanistic arguments run in opposite directions and both remain live. The protective argument holds that MC1R activation increases eumelanin, enhances repair of ultraviolet-damaged DNA and boosts antioxidant defence, so a melanocortin-induced tan should lower melanoma risk — this was the original design rationale, supported by the observation that people with functional MC1R variants are at lower melanoma risk than those with loss-of-function variants. The opposing argument holds that sustained pharmacological stimulation of melanocytes drives their proliferation, producing new and enlarging moles, and that a proliferating melanocyte pool is exactly the substrate from which melanoma arises. Documented eruptive mole formation in users is the strongest evidence for the second view; the absence of any cohort study means neither has been tested at the level of hard outcomes.
Pharmacological properties. Half-life: never formally characterized in published human studies; rat data show a biphasic plasma disposition after intravenous dosing — blood levels fall in two distinct stages, a fast one followed by a slower one (Ugwu et al., 1994) — and the human trial observation that erections occur within one to five hours of a dose is consistent with short circulating persistence. The pigmentary effect long outlasts the drug because melanin, once made, persists through the skin’s renewal cycle. Selectivity: broad, covering four of the five melanocortin receptors. Tissue distribution: a water-soluble peptide with negligible oral bioavailability, given by subcutaneous injection or (less predictably) intranasally; central effects are achieved despite limited blood-brain barrier penetration, most plausibly at hypothalamic sites with a permeable barrier. Metabolism: cleared by peptidases rather than by liver CYP450 enzymes (the cytochrome P450 family that metabolizes most conventional drugs), so the classic CYP3A4-type drug interactions do not apply and interaction risk arises from overlapping effects on the same body systems rather than from competition for the same clearance route.

Historical Context & Evolution

Original intended use. Melanotan I and Melanotan II were designed in the 1980s at the University of Arizona by Mac Hadley, Victor Hruby, Norman Levine and Robert Dorr with an explicitly preventive aim: if a protective tan could be induced pharmacologically, people might achieve pigmentation without the ultraviolet exposure that causes skin cancer. Melanotan I was a linear, MC1R-preferring analogue; Melanotan II was the cyclic, non-selective one.
The self-experimentation episode. The compound’s second life began with an accident. In the course of early human self-experimentation by the Arizona group, a dose produced not only tanning but a prolonged spontaneous erection, an observation the investigators pursued rather than dismissed. It redirected an entire research program from dermatology into sexual medicine.
What the human trials actually found. The pilot phase I study in three men (Dorr et al., 1996) documented measurable increases in facial, upper-body and buttock pigmentation by reflectance one week after only five low subcutaneous doses, alongside mild nausea at most dose levels and a stretching-and-yawning complex that tracked the onset of spontaneous erections lasting one to five hours. Two subsequent double-blind, placebo-controlled crossover studies in men with erectile dysfunction of psychogenic and organic origin (Wessells et al., 1998; Wessells et al., 2000) showed real, measured erectile responses and increased sexual desire. These are small studies, but they are genuine controlled human data, and the findings have never been contradicted by later work — they were simply not followed up for this molecule.
A financial interest that shaped the record. Every one of the human trials above was conducted by the same University of Arizona group that designed and patented the compound and that stood to profit from its licensing. That is a direct financial interest in a favourable result and it must be weighed when reading the efficacy findings. It also cuts the other way: the same group’s candour about nausea rates and dose-limiting toxicity in those papers is not what a purely promotional record looks like.
Where the chemistry ended up. Two approved medicines descend from this program. Melanotan I became afamelanotide (Scenesse), approved in Europe in 2014 and by the U.S. Food and Drug Administration (FDA) in 2019 for erythropoietic protoporphyria (a rare inherited disorder causing severe pain on light exposure). A modified Melanotan II analogue became bremelanotide (Vyleesi), approved by the FDA in 2019 for hypoactive sexual desire disorder (persistently low sexual desire causing distress) in premenopausal women. Melanotan II itself was abandoned as a development candidate — its non-selectivity, its nausea burden and its blood pressure effects made it a poor drug, and the patentable, more selective successors were commercially preferable.
The evolution of opinion is not settled. From roughly 2007 onward the compound reappeared as an internet-sold tanning injection, first in Scandinavia, the United Kingdom, Ireland and Australia, and dermatology journals began publishing case reports of changing moles, eruptive moles and melanoma. Regulators in multiple countries issued warnings. The prevailing clinical view today is that the risks are unacceptable, and that view rests on a real body of case evidence. What changed was the observation of melanocytic lesions in users; what has still not appeared on either side is a cohort study, a registry, or any systematic follow-up of the thousands of people who have used this compound. The current position is a reasonable inference from case reports, not a demonstrated outcome, and it should be read as such.

Expected Benefits

High 🟩 🟩 🟩

Increased Skin Pigmentation Without Ultraviolet Exposure

Melanotan II reliably darkens human skin by activating MC1R on melanocytes and driving eumelanin synthesis, a mechanism that does not depend on ultraviolet light. The phase I study measured increased pigmentation of the face, upper body and buttock by quantitative reflectance and by visual assessment after only five low subcutaneous doses, and the effect is the single most consistently reproduced finding across every human exposure record, controlled or observational. The limitation is that the total controlled human experience amounts to a few dozen men studied for weeks, so the depth, evenness and durability of pigmentation over months of use are described only by user reports. Pigmentation is typically uneven, favouring the face, existing moles and freckles over the trunk.

Magnitude: Visible and reflectance-measurable darkening in 2 of 3 subjects one week after five subcutaneous doses of 0.01–0.03 mg/kg; users typically report visible change within 1–2 weeks and a plateau at 3–4 weeks.

Initiation of Penile Erection in Men With Erectile Dysfunction

Melanotan II initiates erection through central melanocortin pathways rather than through penile blood vessels, meaning it can produce an erection in the absence of sexual stimulation — a pharmacological profile no approved erectile agent shares. Two double-blind, placebo-controlled crossover trials using RigiScan (an instrument that continuously measures penile rigidity) found clinically apparent erections in the large majority of treated men, in both psychogenic and organic erectile dysfunction. The evidence base is small — ten men in each of the two trials, twenty in total — and now more than twenty-five years old, and it was generated by the patent-holding group, but it is randomized, placebo-controlled and objectively instrumented rather than self-reported.

Magnitude: Mean duration of penile tip rigidity above 80% was 38.0 minutes versus 3.0 minutes with placebo in men with psychogenic erectile dysfunction, and 45.3 versus 1.9 minutes in men with organic risk factors; erections occurred in 8 of the 10 men in the psychogenic trial and in 17 of the 20 men pooled across both trials.

Medium 🟩 🟩

Increased Sexual Desire

Beyond mechanical erection, men in the Arizona trials reported a distinct increase in subjective sexual desire after Melanotan II compared with placebo, an effect attributed to melanocortin action on central dopaminergic circuits rather than to any peripheral or hormonal change. This finding is what motivated the development of bremelanotide, the modified analogue later approved specifically for low sexual desire in women, so the mechanism has been independently validated in a much larger regulatory dataset — though for the successor molecule, not for Melanotan II. The desire outcome in the original trials was a questionnaire-based secondary endpoint in a small sample, which is why it does not carry the same weight as the instrumented erection data.

Magnitude: Increased sexual desire reported after 13 of 19 Melanotan II doses (68%) versus 4 of 21 placebo doses (19%), p < 0.01 (p-value: the probability that a difference this large would appear by chance alone).

Low 🟩

Reduced Appetite and Food Intake

Appetite suppression appears in the human trial record as a consistently reported effect rather than as a measured outcome — “decreased appetite” was logged more frequently after Melanotan II than after placebo in the crossover study — and it is strongly supported mechanistically by MC4R biology, the same target as the approved anti-obesity drug setmelanotide. Preclinical work is unambiguous: melanocortin agonism reduces both the motivation to obtain food and the amount consumed. What is missing is any human study that measured food intake, body weight or body composition on Melanotan II, and the systematic review of this receptor family concluded that essentially all of the relevant work remains preclinical. For a longevity-oriented user, appetite reduction is also difficult to separate from nausea, which would produce the same behaviour by an entirely different and unwelcome route.

Magnitude: Not quantified in available studies.

Photoprotection From Increased Eumelanin ⚠️ Conflicted

The founding rationale for the entire melanotan program was that a pharmacologically induced eumelanin tan would absorb ultraviolet radiation and reduce DNA damage, lowering long-term skin cancer risk. For the MC1R-preferring sibling compound, controlled human work has shown reduced markers of ultraviolet-induced DNA damage, and that compound is now an approved medicine for a light-sensitivity disorder — evidence that melanocortin-induced pigment can be genuinely photoprotective. The conflict is that no equivalent protection study exists for Melanotan II, that a cosmetic tan of any origin provides only a modest sun protection factor, and that the very case reports documenting new and changing moles in users point to a countervailing melanocyte-proliferative effect. In practice, users overwhelmingly combine the compound with sunbeds to accelerate results, which inverts any protective intent.

Magnitude: Not quantified in available studies.

Speculative 🟨

Improved Insulin Sensitivity and Metabolic Control

Melanocortin-4 receptor activation improves glucose handling and insulin sensitivity in rodents independently of weight loss, and the leptin–melanocortin axis is a central regulator of metabolic health, making a metabolic benefit mechanistically plausible. No human study has measured glucose, insulin, lipids or insulin sensitivity on Melanotan II, so this rests entirely on animal work and on inference from the approved melanocortin drugs in genetically defined obesity. The same rodent literature that supports a metabolic benefit also shows melanocortin-driven increases in sympathetic outflow and blood pressure, so any metabolic upside is inseparable from a cardiovascular cost in the same models.

Neuroprotective and Cognitive Effects

Melanocortin agonists including Melanotan II promote peripheral nerve regeneration in rats, reverse diet-induced memory impairment in zebrafish, and reduce amyloid pathology and glial reactivity in an Alzheimer’s disease mouse model. This is a coherent preclinical signal across independent laboratories and endpoints, and the melanocortin system is a recognized anti-inflammatory and neuroprotective pathway. There are no controlled human studies of any cognitive or neurological endpoint with this compound; the basis is mechanistic and animal-derived only, and it sits alongside a human case report of a serious brain-swelling syndrome after use, which points in the opposite direction.

Repigmentation in Vitiligo

Because melanocortin signaling drives melanocyte activity, adding a melanocortin agonist to standard light therapy is a rational strategy for repigmenting vitiligo (an autoimmune condition causing patches of pigment loss). The approved MC1R-preferring analogue has advanced to late-stage trials in this indication, and a phase 2 trial of Melanotan II itself as an addition to narrowband ultraviolet B phototherapy began recruiting in 2026. No results exist for either compound in this setting at the time of writing, so the basis is mechanistic plausibility plus an in-progress trial, not evidence of benefit.

Benefit-Modifying Factors

MC1R genotype: The pigmentary response runs entirely through MC1R, so loss-of-function variants of that receptor — the “red hair colour” variants such as R151C, R160W and D294H that are common in fair-skinned northern European populations — blunt or abolish the tanning effect. Paradoxically, the people most motivated to use the compound because they tan poorly are the ones least likely to respond, and they are also the group at highest baseline melanoma risk.
Melanocortin-4 receptor variants: Loss-of-function MC4R variants, present in roughly 1 in 1,000 to 1 in 2,000 people and the commonest monogenic cause of obesity, would be expected to blunt the appetite-suppressing and central sexual effects while leaving pigmentation intact, since those actions run through different receptors.
Baseline skin phototype and melanin index: Response scales with the number and activity of existing melanocytes. Fitzpatrick skin types III and IV (skin that tans readily) show the fastest and most even darkening; types I and II (skin that burns and freckles) tend toward patchy pigmentation, darkened existing moles and new freckles rather than a uniform tan.
Baseline erectile function and testosterone status: The erectile trials enrolled men with established dysfunction, both psychogenic and organic, and both responded. Because the mechanism is central rather than vascular, men whose dysfunction is primarily arterial may still respond, while men with normal function have no measured benefit to gain and only the side effect burden.
Baseline naevus count and dermoscopic status: People with a high existing mole count, as recorded by dermoscopy (examination of moles through a magnifying lens with polarized light), have more melanocytic tissue available to respond, which increases both the cosmetic pigmentary effect and the likelihood of the lesion changes that dominate the harm literature. The same factor moves benefit and risk in the same direction.
Sex: All controlled human efficacy data for Melanotan II were generated in men; the sexual-response findings therefore cannot be assumed to transfer. The approved successor compound demonstrated a desire effect in premenopausal women, which supports biological plausibility for a female response but does not establish it for this molecule. The pigmentary mechanism has no known sex dependence.
Pre-existing health conditions: Obesity is associated with partial resistance to the metabolic and cardiovascular actions of melanocortin agonism in animal models, which may blunt any appetite benefit in the people most interested in it. Conditions involving the pituitary–melanocortin axis, and any condition requiring immunosuppression of the skin, alter the expected response.
Age: Melanocyte density in the skin declines with each decade after early adulthood, so an older user should expect a slower and less complete tanning response than a younger one at the same dose. For users at the older end of a longevity-oriented cohort, this is compounded by decades of accumulated ultraviolet damage, which raises the baseline probability that any newly appearing or changing lesion is clinically significant rather than benign.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Vomiting

Nausea is the most frequently reported adverse effect of Melanotan II, logged at most dose levels in the phase I escalation and in both controlled erectile trials. It is a direct central melanocortin effect, not an injection-site or impurity phenomenon, and it appears within an hour of dosing. It was mild and required no treatment in the phase I study, where somnolence (heavy drowsiness) and fatigue rather than nausea proved dose-limiting, but a minority of subjects experienced severe nausea at the recommended 0.025 mg/kg dose, and it is the single reason most often given by users for abandoning the compound. Severity is dose-related and tends to attenuate over repeated exposures, which is the basis for the community practice of starting at very low doses.

Magnitude: Severe nausea in 12.9% of subjects at 0.025 mg/kg, and in 4 of 19 injections in the organic erectile dysfunction trial; mild nausea at most dose levels tested.

Unwanted Spontaneous Erections With Stretching and Yawning

The stretching-and-yawning complex followed by spontaneous, non-sexual erection is a signature melanocortin effect and occurs in men who took the compound purely for tanning. It is not a rare idiosyncrasy but an expected pharmacological action, documented in the phase I study in men with no sexual complaint. The practical consequence is hours of unpredictable, socially awkward physiology after each dose, and at the upper end it shades into priapism, which is a separate and more serious risk.

Magnitude: Intermittent spontaneous erections for 1–5 hours after dosing, duration increasing with dose, in the phase I study of healthy men.

Somnolence and Fatigue

Dose-related drowsiness and tiredness set in within an hour or two of injection, and these were the effects that capped the dose in the phase I escalation before any other toxicity forced a stop. The mechanism is central melanocortin action on arousal state — the same circuitry that produces the stretching-and-yawning complex — rather than any sedative impurity in the product. The effect is reversible and resolves overnight, which is precisely why evening administration became near-universal practice, but it makes daytime dosing incompatible with driving, training or cognitively demanding work. For a longevity-oriented user the cost is a blunted evening and a slow next morning rather than any lasting harm, though it compounds with the sleep fragmentation that nausea and spontaneous erections cause in the same window.

Magnitude: Somnolence and fatigue were dose-limiting at 0.03 mg/kg subcutaneously in the phase I escalation, setting the recommended dose one step lower at 0.025 mg/kg; onset within 1–2 hours of dosing with overnight resolution.

Darkening of Existing Moles and Eruptive New Moles

The best-documented dermatological harm is not melanoma but melanocytic change: existing moles darken and enlarge, freckles multiply, and crops of new moles erupt, sometimes within weeks of starting. This has been reported in independent case series from multiple countries, including in adolescents and in people with familial atypical mole syndrome (an inherited tendency to many unusual-looking moles and a high melanoma risk), and it is mechanistically predictable from sustained melanocyte stimulation. The clinical problem is compounding: a changing mole is the primary warning sign clinicians use to detect melanoma, and a compound that changes all of them destroys the signal, making subsequent surveillance far harder and driving excisions of lesions that would otherwise never have been touched.

Magnitude: Not quantified in available studies.

Adulterated, Underdosed and Contaminated Product

Because there is no legal manufacturer, every consumer vial comes from an unregulated supply chain, and analytical studies of purchased product show this is not a theoretical concern. Laboratory characterization of vials bought from online shops found both substantial underdosing relative to the label and measurable unidentified impurities. Independent mass-spectrometry work on black-market samples has repeatedly confirmed misidentification and variable content across the melanotan and bremelanotide trade. Sterility and bacterial endotoxin content (endotoxin is a bacterial cell-wall fragment that survives sterilization and causes fever and systemic inflammation when injected) are not tested at all by these suppliers, and the material is injected.

Magnitude: Vials labelled 10 mg contained 4.32–8.84 mg of actual peptide, with unidentified impurities of 4.1–5.9% in product from two of three online shops tested.

Medium 🟥 🟥

Melanoma ⚠️ Conflicted

Multiple independent case reports describe cutaneous melanoma arising in Melanotan II users, typically in young, fair-skinned people, within months of a course of injections; a 2025 report describes an oral mucosal melanoma in a young woman who used the compound as a nasal spray. A narrative review counted four published melanomas emerging from pre-existing moles during or shortly after melanotan use. The conflict is genuine and unresolved: essentially every reported case involved concurrent sunbed use, several involved known high-risk genetics, and case reports cannot establish causation or estimate risk — while the opposing hypothesis, that melanocortin-induced eumelanin should be protective, has real mechanistic support from the MC1R genetics literature. What tips this to a Medium grade despite the weak study design is the combination of a plausible proliferative mechanism, reproducibility of the mole changes that precede such lesions, and the severity of the outcome.

Magnitude: At least four published melanomas arising from pre-existing moles in melanotan users as of 2017, with further cutaneous and mucosal cases since; incidence and relative risk are unquantified as no cohort study exists.

Blood Pressure and Heart Rate Elevation

Melanocortin-4 receptor activation raises sympathetic nervous system outflow, and this is one of the best-established effects of the receptor family in animal work — it is why melanocortin agonists proved difficult to develop as obesity drugs. In humans it manifests as a sympathomimetic picture: raised blood pressure, tachycardia (fast heart rate), sweating, restlessness and pupil dilation, documented in a toxicology case after a six-fold overdose. For a longevity-oriented user, chronic elevation of blood pressure is the mechanism most likely to erode the very endpoints they are optimizing, and it is entirely unmonitored in gray-market use.

Magnitude: Blood pressure 151/85 mmHg and heart rate peaking at 146 beats per minute two hours after a 6 mg subcutaneous dose in a documented overdose case; magnitude at ordinary doses is not quantified.

Facial Flushing, Headache, Injection-Site Reactions and Sebaceous Effects

Flushing of the face and upper body within minutes of injection, headache, local injection-site pain, redness and lumps, and increased skin oiliness with acne flares are the everyday complaints that dominate user accounts. The flushing and the headache are direct vasomotor melanocortin effects; the sebaceous changes are consistent with MC5R activation in oil glands. Headache is listed among the common adverse effects in every drug reference source covering this compound and tracks the same one-to-five-hour window as the flushing, which is why it clusters with nausea in reports of the first few doses. A qualitative analysis of 623 forum entries from 205 users catalogued these as near-universal accompaniments of use, alongside more concerning practices. These effects are self-limiting and reversible but they are the reason the compound is difficult to use discreetly.

Magnitude: Not quantified in available studies.

Priapism

Priapism — a sustained, painful erection lasting beyond four hours — has been documented in several independent case reports following Melanotan II injection, including after deliberate overdose and after ordinary dosing. It is a urological emergency: ischaemia (loss of blood supply and therefore of oxygen) of the erectile tissue beyond roughly four to six hours causes irreversible fibrosis (replacement of working tissue by scar) and permanent erectile dysfunction, the precise opposite of the effect sought. The mechanism is a straightforward extension of the compound’s central pro-erectile action, and the risk is amplified by the underdosing-and-redosing behaviour that unreliable product encourages, and by concurrent use of erectile drugs.

Magnitude: At least three independent published case reports, with episodes requiring emergency urological intervention; incidence at ordinary doses is unquantified as no cohort data exist.

Low 🟥

Rhabdomyolysis and Acute Kidney Injury

A documented case describes systemic sympathomimetic toxicity with muscle breakdown and renal impairment following a single subcutaneous injection, with the injected material subsequently confirmed by mass spectrometry to be genuine Melanotan II rather than an adulterant. Rhabdomyolysis is a recognized consequence of severe sympathomimetic states, so the mechanism is coherent, but this rests on isolated reports at supratherapeutic doses rather than on any systematic data. The risk is likely amplified in users who train intensely, since strenuous exercise is itself a rhabdomyolysis trigger.

Magnitude: Peak creatine kinase (an enzyme that leaks into the blood when muscle fibres break down) 17,773 IU/L (from 1,760 IU/L on presentation) with creatinine rising to 2.25 mg/dL, requiring three days of intensive care, after a 6 mg dose.

Renal Infarction

A published case report with accompanying literature review attributes a renal infarction to Melanotan II, proposing either a thrombotic effect or direct toxicity to kidney tissue. This is a single case in a compound used by many thousands of people, so the absolute risk is presumably very low, but the outcome is serious and the vascular mechanism is consistent with the compound’s documented sympathomimetic and vasomotor activity. It joins rhabdomyolysis as a second independent route to kidney injury.

Magnitude: One published case report with accompanying literature review; incidence is unquantified as no cohort data exist.

Posterior Reversible Encephalopathy Syndrome

A case report in a major internal medicine journal links melanotan use to posterior reversible encephalopathy syndrome (a brain-swelling disorder causing headache, visual disturbance, confusion and seizures), which is classically triggered by acute blood pressure surges. The proposed mechanism is the compound’s sympathetic and pressor activity overwhelming cerebral autoregulation (the brain’s ability to hold its own blood flow steady as blood pressure changes). The syndrome is usually reversible with prompt blood pressure control, but it can leave permanent deficits, and this is an isolated report rather than a characterized risk.

Magnitude: One published case report; incidence is unquantified as no cohort data exist.

Blood-Borne Infection From Injection Practice

The qualitative forum analysis documented needle reuse, needle sharing, non-sterile reconstitution and dosing from vials of unknown provenance among Melanotan II users, and this behavioural cluster is well characterized in the wider injectable appearance-enhancement literature. The risk is not pharmacological — it is hepatitis B, hepatitis C, human immunodeficiency virus and local abscess formation from unsterile technique in a population that does not see itself as injecting drug users and therefore does not access needle exchange or testing services.

Magnitude: Not quantified in available studies.

Melanonychia and Nail Pigmentation

Melanonychia (brown to black pigmented bands running the length of a nail) is a recognised consequence of Melanotan II use and is listed among the documented long-term effects in standard dermatology references. The mechanism is the same melanocyte stimulation that darkens skin and moles, applied to the melanocytes of the nail matrix, so the change is pharmacologically expected rather than idiosyncratic. It is cosmetically benign in itself and fades slowly as the nail grows out, but it carries the same surveillance cost as the mole changes: a new or widening pigmented nail band is the classic presenting sign of subungual melanoma (melanoma arising under the nail), and a compound that produces such bands in healthy nails removes the value of that sign.

Magnitude: Not quantified in available studies.

Speculative 🟨

Mucosal and Ocular Pigmentary Change

Isolated case reports describe pigmentary changes in the lining of the mouth in Melanotan II users, and melanocytes are present in mucosal surfaces, the eye and the inner ear as well as the skin. Whether systemic melanocortin stimulation meaningfully alters melanocytes at these sites, and whether such changes carry any clinical consequence, is entirely unknown. The basis here is a small number of isolated reports and mechanistic reasoning, with no controlled data of any kind.

Long-Term Cardiovascular and Renal Remodeling

Chronic melanocortin-4 receptor activation raises sympathetic tone persistently in animal models, and sustained sympathetic activation is a recognized driver of cardiac hypertrophy (thickening of the heart muscle), arterial stiffening and progressive kidney damage over years. No human has ever been followed prospectively on this compound for longer than a few weeks, so whether intermittent use over years produces any of this is unknown. The concern is a mechanistic extrapolation from receptor pharmacology, not an observed finding.

Risk-Modifying Factors

MC1R loss-of-function variants: Carriers of the red-hair-colour variants have both a blunted tanning response and a substantially elevated baseline melanoma risk. This combination is the worst possible risk-benefit position: less of the desired effect, more dose escalation to chase it, and a higher-risk melanocyte population being stimulated.
CDKN2A mutations and familial atypical multiple mole melanoma syndrome: CDKN2A (a tumour-suppressor gene that normally restrains melanocyte division) is the commonest known melanoma-predisposition gene, and a published case documented marked changes in melanocytic lesions in a teenager with this inherited high-risk syndrome after melanotan injection combined with sunbed use. In anyone with a family history of melanoma or a known high-risk genotype, the mole-changing effect converts an already difficult surveillance problem into an unmanageable one.
Baseline blood pressure and vascular biomarkers: Pre-existing hypertension is the modifier most likely to convert the compound’s sympathetic activation into a clinical event, whether that is the brain-swelling syndrome described above or an ordinary cardiovascular one. Baseline kidney function matters equally, since a reduced renal reserve makes the rhabdomyolysis and infarction pathways far less survivable.
Baseline naevus count and dermoscopic mapping status: Someone with more than about 50 moles, or with clinically atypical moles, has both more tissue to respond and a much higher pre-test probability that any change represents something serious. Without a documented dermoscopic baseline, the changes this compound causes cannot be distinguished from the changes clinicians look for.
Sex: Priapism and the spontaneous-erection burden are male-specific risks and are the harms most likely to require emergency care. Women lack these but have no compensating safety advantage: the pigmentary, gastrointestinal and cardiovascular effects apply equally, and the published melanoma and mucosal melanoma cases in the melanotan literature span both young women and middle-aged men, which reflects the demographics of use rather than any biological difference.
Pre-existing health conditions: Sickle cell disease or trait, myeloproliferative disorders (conditions in which the bone marrow overproduces blood cells, thickening the blood) and other priapism-predisposing conditions markedly amplify the erectile risk. Any personal history of melanoma or non-melanoma skin cancer, any immunosuppression, chronic kidney disease, uncontrolled hypertension, recent cardiac events and a history of seizures each convert a low-probability harm into a foreseeable one.
Age: Older users carry more cumulative ultraviolet damage, a higher background rate of atypical lesions and a higher prevalence of hypertension and vascular disease, so both the dermatological and cardiovascular risk profiles worsen with age while the pigmentary benefit weakens. For users at the older end of a longevity-focused cohort, the risk-benefit ratio is therefore materially worse than for the young cosmetic users who generate most of the anecdotal experience.

Key Interactions & Contraindications

PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil): Caution bordering on avoidance. Central pro-erectile action stacked onto peripheral vasodilation additively increases both erection duration and the probability of priapism, and the combination also lowers blood pressure more than either alone. Mitigating action: a separation of at least 24 hours where either is used, and no combination while a Melanotan II dose is first being established.
Alpha-blockers (tamsulosin, doxazosin, alfuzosin — drugs that relax smooth muscle in blood vessels and the prostate) and nitrates (nitroglycerin, isosorbide mononitrate — drugs that widen blood vessels to relieve chest pain): Caution. Both classes are independently associated with priapism and with orthostatic hypotension (a drop in blood pressure on standing), and both are commonly co-prescribed in the older men most interested in the erectile effect. Mitigating action: night-time dosing while recumbent, with standing blood pressure monitored.
Antihypertensive medications (amlodipine, lisinopril, losartan, metoprolol): Monitor. Melanotan II raises sympathetic outflow and can oppose blood pressure control, potentially unmasking previously controlled hypertension. Mitigating action: home blood pressure monitoring at baseline and weekly during the first month of use.
Stimulants and sympathomimetics (amphetamine, methylphenidate, cocaine, pseudoephedrine, high-dose caffeine): Caution. Additive sympathetic activation raises the risk of the hypertensive, tachycardic and rhabdomyolysis picture documented in the toxicology literature. Mitigating action: avoidance of same-day use; this is the single most important interaction in the population that actually uses this compound.
Drugs independently associated with priapism (trazodone, chlorpromazine, risperidone, hydralazine): Caution. The risks compound and the resulting episode is more likely to exceed the four-hour irreversibility threshold. Mitigating action: if these cannot be discontinued, the combination should be treated as an avoidance.
Over-the-counter medications: Caution. Pseudoephedrine and phenylephrine (decongestants) add sympathetic load; first-generation antihistamines (diphenhydramine, chlorphenamine) may interact with the histamine-dependent thermoregulatory effect demonstrated in mice, with unpredictable direction in humans; non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) do not interact directly but compound renal risk if rhabdomyolysis occurs. Mitigating action: paracetamol rather than a non-steroidal agent for headache during a dosing course, with hydration maintained.
Supplements with additive erectogenic effect (yohimbine, L-Arginine, L-Citrulline, Panax ginseng, Tribulus terrestris, icariin): Caution. Each independently promotes erection by vascular or adrenergic routes and adds to priapism risk. Yohimbine additionally raises blood pressure and heart rate, making it the most concerning of the group. Mitigating action: discontinuation of erectogenic supplements before initiation.
Supplements with additive sympathetic or thermogenic effect (synephrine and bitter orange, high-dose caffeine, ephedra-type products, high-dose green tea extract): Caution. Additive pressor and tachycardic effects, with the same clinical consequence as the stimulant interaction. Mitigating action: separation of stimulant intake from dosing by at least six hours.
Supplements affecting pigmentation or melanocytes (copper, tyrosine, high-dose beta-carotene marketed for tanning): Monitor. These are commonly stacked by the same users and provide no demonstrated additive benefit, but copper is a tyrosinase cofactor and chronic supplementation beyond requirement carries its own toxicity. Mitigating action: no copper supplementation beyond dietary intake.
Other interventions — ultraviolet exposure and sunbeds: Absolute avoidance in combination. Every published melanoma case in melanotan users involved concurrent sunbed exposure, and the combination pairs a melanocyte-proliferative stimulus with a mutagenic one. Mitigating action: no sunbed use during or for at least three months after a dosing course.
Other interventions — GLP-1 receptor agonists (semaglutide, tirzepatide) and other appetite-suppressing agents: Caution. These drugs mimic glucagon-like peptide-1 (a gut hormone that signals fullness). Nausea and appetite suppression are additive, and the combination readily produces intake low enough to cost lean mass. Mitigating action: no initiation of both within the same eight-week window, with protein intake tracked.
Populations who should avoid this intervention: Anyone with a personal history of melanoma or of dysplastic naevus syndrome (a pattern of many irregular moles carrying elevated melanoma risk); anyone with a first-degree relative with melanoma or a known CDKN2A mutation; anyone with more than 50 melanocytic naevi or clinically atypical moles; Fitzpatrick skin type I with a history of blistering sunburn; uncontrolled hypertension (blood pressure above 140/90 mmHg on repeated measurement); a cardiovascular event within 90 days; chronic kidney disease with an estimated glomerular filtration rate (eGFR, a calculated measure of kidney filtering capacity) below 60 mL/min/1.73 m²; sickle cell disease or trait or any other priapism-predisposing condition; a prior episode of priapism or of posterior reversible encephalopathy syndrome; pregnancy, attempted conception or breastfeeding; and anyone under 18 years of age.

Risk Mitigation Strategies

Full-body dermoscopic mole mapping before the first dose: A dated photographic and dermoscopic baseline of the entire skin surface, performed by a dermatologist, is the only measure that preserves the ability to interpret the mole changes this compound reliably causes. Without it, the near-universal darkening and eruption of naevi makes later assessment of any single lesion effectively impossible, which is the direct route to a delayed melanoma diagnosis.
Scheduled dermatological surveillance during and after use: Repeated mapped skin examination at 3 months and then every 6–12 months for at least three years after the last dose, with immediate assessment of any lesion showing asymmetry, border irregularity, colour variegation, diameter above 6 mm or evolution. This mitigates the surveillance blindness created by generalized pigmentary change.
Very low starting dose with slow escalation: Beginning far below the 0.025 mg/kg trial dose — community protocols typically start at 100–250 µg and hold there for several days before any increase — mitigates the dose-related nausea, somnolence and blood pressure response that caused dose limitation in the phase I study, and reduces the chance of the sympathomimetic toxicity syndrome documented after a six-fold overdose.
Evening administration: Dosing 1–2 hours before sleep mitigates the practical impact of nausea, flushing, somnolence and spontaneous erection by shifting the 1–5 hour window of peak effect into sleep, and reduces the risk of driving or working while affected.
Blood pressure and heart rate monitoring: Home measurement at baseline, then before and two hours after dosing during the first two weeks, and weekly thereafter, with discontinuation if resting blood pressure rises above 140/90 mmHg. This mitigates the sympathetic pressor effect and the brain-swelling syndrome that acute pressure surges can precipitate.
Independent third-party analysis of the product: Submitting a sample from each new vial or batch for mass-spectrometry identity and purity testing, and rejecting any product without a batch-specific certificate of analysis, mitigates the documented underdosing of 4.32–8.84 mg against a 10 mg label and the 4.1–5.9% unidentified impurity content found in online-purchased vials.
Strict single-use sterile injection technique: New sterile needle and syringe for every injection, bacteriostatic water for reconstitution, alcohol preparation of both the vial septum and the skin, refrigeration of reconstituted product, and no sharing of any equipment under any circumstances. This mitigates the hepatitis B, hepatitis C, human immunodeficiency virus and abscess risks documented in the injecting appearance-enhancement population.
Complete avoidance of concurrent ultraviolet exposure: No sunbed use and disciplined sun protection with a broad-spectrum sun protection factor of 30 or above throughout the dosing course and for three months afterwards. This mitigates the melanoma risk, which in every published case arose against a background of concurrent tanning-bed exposure.
A pre-agreed priapism escalation plan: Any erection persisting beyond two hours warrants cold application and cessation of dosing; beyond four hours it requires emergency urological assessment, since ischaemic damage becomes irreversible in the four-to-six hour range. This mitigates the permanent erectile dysfunction that is the end point of an untreated episode.
Baseline and periodic kidney and muscle laboratory testing: Creatinine, estimated glomerular filtration rate and creatine kinase at baseline and at 4 weeks, with immediate testing if muscle pain, dark urine or reduced urine output occurs. This mitigates the rhabdomyolysis and renal injury pathways by catching them at a subclinical stage.
Avoidance of stimulants and erectogenic agents during dosing courses: Removing caffeine above 200 mg per day, synephrine-containing thermogenics, yohimbine and PDE5 inhibitors from the same 24-hour window mitigates the additive sympathomimetic and priapism risks that account for most of the reported acute harm.

Therapeutic Protocol

No legitimate clinical protocol for Melanotan II exists, because the compound was never approved anywhere and no practitioner can lawfully prescribe it. What follows are the two distinct approaches that do exist in practice — the published clinical-trial regimen and the gray-market community regimen — presented as alternatives, since neither has been validated against the other.

The published clinical-trial regimen: The University of Arizona group, which designed the compound and ran every human trial, settled on 0.025 mg/kg subcutaneously as the recommended dose after the phase I escalation found 0.03 mg/kg dose-limiting for somnolence and fatigue. For a 70 kg adult this is approximately 1.75 mg per dose — substantially higher than what gray-market users take. Dosing in the tanning study was daily on weekdays for two consecutive weeks with alternating placebo days; the erectile studies used single doses as needed.
The gray-market community regimen: The approach that circulates in online user communities, and which has no published origin or validation, inverts the trial logic: a “loading” phase of 100–250 µg daily until the desired pigmentation is reached, typically over two to four weeks, followed by a “maintenance” phase of 250–1,000 µg once or twice weekly. The rationale offered is tolerability rather than efficacy, and in practice it works because pigmentation accumulates over repeated small stimuli. This is roughly one-tenth of the trial dose per administration.
Route and reconstitution: Both approaches use subcutaneous injection of a lyophilized powder reconstituted with bacteriostatic water, typically into abdominal or thigh subcutaneous tissue. Intranasal preparations circulate but deliver an unknown and highly variable fraction of the stated dose, and the one reported mucosal melanoma involved a nasal spray.
Best time of day: Evening dosing, one to two hours before sleep, is near-universal in practice for both approaches. The rationale is that the nausea, flushing, somnolence, yawning and spontaneous erection all peak in the one-to-five-hour window after administration, and sleeping through that window is the only effective management for effects that have no antidote.
Half-life and dosing frequency: Human pharmacokinetics have never been published; rat data show biphasic plasma disposition after intravenous dosing and human effects resolve within hours, indicating short circulating persistence. The pigmentary effect, however, is carried by melanin already deposited in the skin and therefore persists for weeks after the last dose. This dissociation is why intermittent maintenance dosing works and why daily dosing is unnecessary once pigment is established.
Single versus split dosing: Splitting a dose is the standard tolerability strategy in community practice, since nausea and flushing scale with peak concentration rather than with total exposure. The clinical trials used single subcutaneous doses. There is no evidence that splitting reduces total efficacy, and mechanistically none would be expected for a pigmentary endpoint that integrates repeated stimulation.
Genetic influences on dose choice: MC1R genotype is the dominant pharmacogenetic factor. Carriers of loss-of-function MC1R variants will require more drug for less pigmentary response, and the correct inference from a poor response in such a person is that the compound is a poor fit, not that the dose should be raised. No commercial pharmacogenetic panel routinely reports MC1R status, so hair and skin phenotype serve as the practical proxy.
Sex-based differences in protocol: All dosing data derive from men, and no dose-finding work of any kind has been done in women. Because the compound is dosed by body weight in the trial regimen, and women on average have lower lean mass, the same fixed community dose delivers a higher effective exposure — a plausible reason women report the nausea and flushing burden more prominently in user accounts.
Age-related considerations: Older users should expect a weaker pigmentary response at any given dose because melanocyte density declines with age, creating pressure toward dose escalation precisely in the group least tolerant of the blood pressure and sympathetic effects. For users beyond middle age, and particularly those with any vascular disease, the trial-level dose has no safety data whatsoever in that population.
Baseline biomarker influences on response: Baseline melanin index and Fitzpatrick phototype predict the pigmentary response better than any other measurable variable; baseline blood pressure predicts tolerability; and baseline erectile function determines whether the sexual effect will register as a benefit or an unwanted side effect.
Pre-existing conditions influencing response: Obesity is associated with partial resistance to melanocortin metabolic and cardiovascular signaling in animal models, which may reduce the appetite effect without reducing the pigmentary one. Any inflammatory or autoimmune skin condition alters melanocyte behaviour unpredictably, and any condition treated with immunosuppression raises the stakes on the melanocytic changes the compound produces.

Discontinuation & Cycling

Intended duration of use: Melanotan II is used in courses rather than continuously. There is no rationale, and no safety data, for indefinite use; the entire published human experience covers periods of days to a few weeks, and the longest documented exposures come from user reports rather than any structured record.
Withdrawal effects: No withdrawal syndrome, dependence or rebound phenomenon has been documented. The compound does not act on reward pathways in the manner of dependence-forming drugs, and stopping produces no reported physical symptoms. The appetite suppression reverses on cessation, which can produce a rebound in food intake relative to the suppressed state.
Tapering: No taper is required or described, and none would be pharmacologically justified given the absence of withdrawal effects and the short circulating persistence of the peptide. Dosing simply stops.
Fading of the effect after cessation: Pigmentation fades gradually over one to three months as the epidermis renews and pigmented cells are shed, with the face and existing moles retaining colour longest. This fade rate, not any pharmacological consideration, is what determines the interval before a further course in practice.
Cycling for maintained efficacy: Community practice uses a loading-then-maintenance structure rather than true cycling, and there is no evidence of tachyphylaxis (loss of effect with continued exposure) at the pigmentary target that would make cycling necessary. Nausea does attenuate with repeated exposure, so an interruption may partially reset tolerability in the unwanted direction.
A distinct argument for scheduled breaks: Independent of efficacy, deliberate off-periods of at least three months serve a surveillance function. Melanocytic lesions need a period of no stimulation before a dermatologist can assess whether a changing mole is settling or progressing, and continuous use denies that window entirely.

Sourcing and Quality

No legitimate source exists: There is no approved Melanotan II product in any jurisdiction, no pharmaceutical manufacturer, and no compounding pharmacy that can lawfully prepare it in the United States, the European Union, the United Kingdom or Australia. Every consumer-accessible source is a “research use only” chemical supplier operating in a regulatory gray zone, and the labelling explicitly disclaims human use. This is the single most important sourcing fact about this compound and it has no workaround.
What the analytical evidence shows about actual product: Laboratory characterization of vials purchased from three online shops found actual peptide content of 4.32–8.84 mg against a uniform 10 mg label claim, with unidentified impurities of 4.1–5.9% in product from two of the three. Subsequent high-resolution mass-spectrometry work on seized and purchased black-market samples across the melanotan and bremelanotide trade has repeatedly found misidentification and inconsistent content, and falsified biotechnology injectables are a documented and growing category.
What to look for if the product is obtained anyway: A batch-specific certificate of analysis showing identity confirmed by liquid chromatography with tandem mass spectrometry, purity above 98% by high-performance liquid chromatography, quantified peptide content by mass rather than by vial-fill assumption, and — most neglected — a bacterial endotoxin result. Endotoxin survives sterilization and is therefore not excluded by a sterile-filtration step, and no gray-market supplier tests for it as standard.
Physical quality indicators: Genuine lyophilized peptide is a white, uniform cake or powder that dissolves clear and without residue in bacteriostatic water. Yellowing, a collapsed or oily cake, visible particulates after reconstitution, or a vial without an intact crimp seal are all grounds for rejection. These are crude checks that catch gross problems and nothing more; they cannot detect underdosing or impurity.
Independent verification rather than brand trust: Because there are no regulated brands, brand reputation in this market is reputation among anonymous forum users rather than any verified quality system. Submitting a sample from each batch to an independent analytical laboratory that offers consumer peptide testing is the only meaningful quality control available, and it costs a substantial fraction of the product price.
The regulated alternative: The one α-MSH analogue available through a legitimate supply chain is afamelanotide (Scenesse), a subcutaneous implant supplied only through certified specialist centres for erythropoietic protoporphyria. It is not obtainable for cosmetic tanning, it is MC1R-preferring rather than non-selective, and it is priced as an orphan drug — but it is the only member of this chemical family for which manufacturing quality, identity and sterility are actually assured.

Practical Considerations

Time to effect: Sexual and erectile effects appear within one to five hours of a single dose. Pigmentary change is visible within one to two weeks of daily low-dose administration and typically plateaus at three to four weeks; the appetite effect is immediate but is not reliably separable from nausea in the first days.
Common pitfall — treating the tan as sun protection: A cosmetic tan of any origin provides a sun protection factor in the low single digits, and the compound has never been shown to reduce ultraviolet-induced DNA damage in humans. Users who reduce sunscreen use because they are darker are increasing their ultraviolet dose while simultaneously stimulating their melanocytes.
Common pitfall — combining with sunbeds to accelerate results: This is the near-universal community practice and it is the single behaviour common to every published melanoma case in melanotan users. It converts a compound with contested cancer risk into a compound used alongside a known carcinogen.
Common pitfall — dose escalation in poor responders: Someone with loss-of-function MC1R variants will not tan well no matter the dose, but will experience the full nausea and blood pressure burden. Escalating in pursuit of a response that the receptor genetics preclude is how ordinary use becomes the overdose picture described in the toxicology literature.
Common pitfall — skipping the dermatological baseline: Users almost never establish a mapped skin baseline before starting, which permanently degrades the value of every subsequent skin examination. This is a one-time, low-cost step that cannot be recovered retrospectively.
Common pitfall — assuming the vial contains what the label says: Underdosed product invites escalation, and a subsequent batch at genuine potency then delivers a much larger effective dose at the same nominal number. This dose inconsistency between batches is a mechanism of accidental overdose specific to unregulated supply.
Regulatory status: Melanotan II is not approved for human use in any jurisdiction. The FDA has issued warning letters to vendors marketing it, stating that there is no evidence it is generally recognized as safe and effective; the United Kingdom’s Medicines and Healthcare products Regulatory Agency treats its sale as unlawful; and Australia’s Therapeutic Goods Administration has issued consumer warnings and enforcement actions. It is not a dietary supplement and cannot be lawfully sold as one. Importation for personal use sits in a jurisdiction-dependent gray area and has resulted in seizures.
Cost and accessibility: The compound is inexpensive and trivially accessible — typically USD 20–60 for a 10 mg vial from online suppliers, enough for a full loading and maintenance course. Cost is therefore not a limiting factor in any respect; the meaningful costs are the independent laboratory testing that responsible use would require and the dermatological surveillance that should accompany it, both of which exceed the price of the compound several times over.

Interaction with Foundational Habits

Sleep: Direct and bidirectional. The phase I study documented dose-related somnolence and fatigue, and a stretching-and-yawning complex, all consistent with central melanocortin effects on arousal state — which is why evening dosing is standard practice. Working against this, nausea, flushing and spontaneous erections in the one-to-five-hour window fragment sleep in the same period, and the sympathetic activation raises heart rate at a time when it should be falling. The practical approach in use is dosing one to two hours before bed on a non-training evening, with persistent night-time heart rate elevation on a wearable treated as a signal for dose reduction.
Nutrition: Direct and blunting. Melanocortin-4 receptor activation suppresses appetite centrally, and nausea suppresses it further by an unrelated route, so total intake falls without any deliberate decision. For a longevity-oriented user, the risk is protein intake dropping below the threshold needed to maintain lean mass during a period of reduced total energy. Practical measures: explicit protein tracking rather than reliance on appetite, protein front-loaded into the morning and midday meals ahead of the evening dose, and ginger or an antiemetic rather than reduced intake treated as a benefit. Adequate fluid intake matters independently because of the rhabdomyolysis and renal signal.
Exercise: Indirect and potentially adverse. There is no evidence that the compound blunts or enhances training adaptation directly, but two indirect interactions matter. Reduced energy and protein intake during a dosing course undermines recovery and hypertrophy, and the sympathomimetic state combined with strenuous resistance or endurance training compounds the rhabdomyolysis risk documented in the toxicology case literature. Practical measures: no dosing on the evening of a maximal-effort or novel high-volume session, maintained hydration, and unusually severe or prolonged muscle soreness with dark urine treated as a reason for immediate testing rather than as ordinary training soreness.
Stress management: Largely indirect. Melanotan II acts on melanocortin receptors that share a precursor protein with the stress hormone ACTH, but it has negligible activity at the ACTH receptor itself, so a direct cortisol effect is not expected and none has been demonstrated. The relevant interaction is in the opposite direction: the compound raises sympathetic tone, and a documented overdose case featured marked anxiety and restlessness, so it adds to rather than subtracts from physiological stress load. Practical measures: down-regulating practices such as slow breathing or heat exposure in the hours after dosing address the sympathetic surge directly, and periods of high life stress or poor sleep are the wrong time to begin a course.

Monitoring Protocol & Defining Success

Before any use, a baseline should be established across three domains: a mapped dermatological examination that documents every melanocytic lesion photographically and dermoscopically, a cardiovascular baseline of resting blood pressure and heart rate measured at home across several days, and a laboratory panel covering kidney function, muscle enzymes and metabolic status. The dermatological baseline is the one that cannot be reconstructed later, since the compound alters the very lesions that would need to be compared.

Ongoing monitoring follows a front-loaded cadence: blood pressure before and two hours after dosing daily for the first two weeks, then weekly; laboratory testing repeated at 4 weeks and at 12 weeks during a course; and mapped dermatological review at 3 months, then every 6–12 months for at least three years after the last dose.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Mapped naevus count and dermoscopy	No new or evolving lesions versus baseline	Detects the compound’s characteristic melanocytic changes and preserves melanoma surveillance	Full-body photography plus dermoscopy by a dermatologist; the single non-negotiable baseline; compare images side by side rather than relying on recall
Resting blood pressure	Below 120/80 mmHg	Captures the sympathetic pressor effect, the mechanism behind the reported brain-swelling case	Home cuff, seated, after 5 minutes rest, morning and 2 hours post-dose; conventional treatment thresholds start only at 140/90 mmHg, which is far too permissive here
Resting heart rate	50–65 bpm (beats per minute)	Tracks sympathetic activation, which rises before blood pressure does	Wearable overnight average is more sensitive than a spot reading; conventional normal extends up to 100 bpm, which is far too permissive here; a sustained rise of more than 5 bpm from baseline warrants dose reduction
Creatine kinase (CK)	60–200 U/L	Detects muscle breakdown before it reaches the kidney-damaging range	CK is an enzyme released when muscle fibres are damaged; conventional upper limits reach 400 U/L; do not test within 72 hours of heavy resistance training, which raises it independently
Serum creatinine and eGFR	Creatinine 0.7–1.1 mg/dL; eGFR above 90 mL/min/1.73 m²	Detects the kidney injury reported after both muscle breakdown and renal infarction	eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering capacity; conventional labs flag eGFR only below 60; best paired with CK and with a urine dipstick for blood
Fasting insulin and HOMA-IR	Insulin 2–5 µIU/mL; HOMA-IR below 1.5	Tests the speculative metabolic claim rather than assuming it	HOMA-IR is the homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin; requires a 10–12 hour fast; conventional panels rarely include fasting insulin at all
25-hydroxyvitamin D	40–60 ng/mL	A pharmacological tan darkens skin without any vitamin D being made, and darker skin then reduces synthesis from real sun exposure	Conventional sufficiency is set at 30 ng/mL; draw at the same season year over year since levels swing with sunlight; particularly relevant in users who also reduce ultraviolet exposure
Total and free testosterone (men)	Total 600–900 ng/dL; free 15–25 ng/dL	Establishes whether an erectile complaint is hormonal before attributing any response to this compound	Draw fasting between 7 and 10 a.m., when levels peak; conventional reference ranges extend down to 300 ng/dL, which tolerates clearly symptomatic levels

Qualitative markers matter at least as much as the laboratory panel here, since the effects users care about and the harms that present first are both subjective:

Evenness and distribution of pigmentation, particularly whether darkening is concentrating in existing moles and freckles rather than spreading uniformly
Appearance of any new pigmented lesion, or change in the colour, size, border or symmetry of an existing one
Appearance or widening of a pigmented longitudinal band in any fingernail or toenail
Severity and duration of nausea after each dose, and whether it is attenuating or worsening across a course
Appetite, and specifically whether total food and protein intake is being maintained
Libido and erectile function, distinguishing wanted from unwanted spontaneous responses
Sleep quality and continuity in the hours following an evening dose
Energy, restlessness and anxiety in the day after dosing, as a subjective proxy for sympathetic load
Skin oiliness and acne, which track the sebaceous melanocortin effect

Defining success is straightforward and is settled in advance rather than retrospectively: the desired pigmentary or sexual effect achieved at the lowest dose that produces it, with blood pressure unchanged from baseline, laboratory markers stable, and no new or evolving melanocytic lesion. Failure to reach the desired effect within four weeks of consistent low dosing, or any evolving skin lesion at any point, are both stopping criteria rather than reasons to adjust.

Emerging Research

For a health- and longevity-oriented user, the research that matters is not whether melanocortin agonism works — that is settled — but whether it can be made selective enough to keep the pigmentary or metabolic effect while shedding the melanocyte-proliferative and cardiovascular liabilities. Every active line below bears on that question, and they point in both directions.

First controlled trial of Melanotan II in more than two decades: A randomized, double-blind, placebo-controlled phase 2 study of Melanotan II as an addition to narrowband ultraviolet B phototherapy in adults with stable non-segmental vitiligo began recruiting in February 2026 (NCT07437560, 60 participants, primary endpoint change in Vitiligo Area Scoring Index at 24 weeks, with focused skin examinations including naevus monitoring as a safety endpoint). This is the first registered interventional trial of this specific compound in a generation, and its safety data — collected under blinded, monitored conditions with structured mole surveillance — would be the first evidence on the melanocytic question that does not come from case reports. Its exclusion criteria are themselves informative: prior melanoma, dysplastic naevus syndrome and uncontrolled hypertension all bar entry.
The selective comparator in the same indication: A phase 3 trial of afamelanotide combined with narrowband ultraviolet B versus phototherapy alone in vitiligo (NCT06109649, 200 participants, active and no longer recruiting) is testing the MC1R-preferring analogue in the same setting. Read alongside the Melanotan II trial, it will indicate whether receptor non-selectivity buys any additional pigmentary benefit or only additional side effects — the central open question about this compound’s design.
Selective melanocortin agonists as the successor strategy: A phase 2a study of the MC1R-selective agonist PL-8177 in active ulcerative colitis (NCT05466890, 16 participants, Palatin Technologies) is testing the anti-inflammatory arm of melanocortin biology with a molecule engineered to avoid the central receptors. A positive result would strengthen the case that the therapeutic value in this family lies in selective agents, and would further undercut any rationale for a non-selective one.
Central melanocortin agonism for appetite in humans: A phase 2 study of setmelanotide in Prader-Willi syndrome (a genetic disorder whose central feature is relentless hunger and early obesity) (NCT06772597, 18 participants, Rhythm Pharmaceuticals) continues to define what MC4R activation does to human appetite and body weight under controlled conditions. This is the closest available human read on the appetite claims made for Melanotan II, and it comes with a fully characterized adverse event profile that Melanotan II lacks — including the skin hyperpigmentation that is an expected class effect.
Research that could weaken the case for the compound: The absence of any cohort or registry study of melanotan users remains the largest gap, and the dermatology literature continues to accumulate case-level signal, most recently a mucosal melanoma reported after intranasal use (Yassin Alsabbagh et al., 2025) and oral mucosal pigmentary change (Bonchev, 2026). A properly designed retrospective cohort drawn from dermatology clinics in the countries with the highest use — Ireland, the United Kingdom, Denmark and Australia — is the study most likely to settle the melanoma question in either direction, and no such study is registered.
Research that could strengthen the case for the compound: The preclinical literature on melanocortin agonism in cognition and neuroprotection continues to expand, including reversal of diet-induced memory impairment by Melanotan II specifically in zebrafish (Wekwejt et al., 2023) and reduction of amyloid pathology and glial reactivity by melanocortin receptor activation in an Alzheimer’s disease mouse model (Lau et al., 2021). If any of this translated, the risk-benefit calculation for a longevity-focused user would change materially. Translation from animal melanocortin neuroscience to human cognition has no successful precedent to date, so this remains the most speculative of the active directions.
Analytical surveillance of the illicit supply: Ongoing forensic characterization of black-market melanotan and bremelanotide products (Mestria et al., 2021; Deville & Charlier, 2024) is the only research stream that directly addresses what users are actually injecting. It will not change the pharmacology, but it is the work most likely to change practical risk estimates, since a large share of reported harm may be attributable to what is in the vial rather than to the peptide itself.

Conclusion

Melanotan II is a laboratory-made copy of the body’s own pigment signal, built in the 1980s in the hope that a tan produced without sunlight might reduce skin cancer. It does darken skin reliably, and small but properly controlled studies in men showed that it also triggers erections and raises sexual desire. Those findings are real, but the total controlled human experience amounts to a few dozen people studied over weeks, and it was produced by the same university team that owned the patents — a financial interest that cuts in favour of the benefits reported. Later commercial effort went to two more selective descendants that became approved medicines, so no company had reason to fund further study of this compound.

Against that sits a consistent harm record: near-universal nausea, unwanted erections, rising blood pressure, and a well-documented tendency for moles to darken and multiply, which both worries clinicians directly and destroys the visual signal used to catch skin cancer early. Isolated reports describe muscle breakdown, kidney damage, brain swelling and melanoma, always alongside sunbed use. Because nothing sold is made under any quality standard, what a user injects is often not what the label says.

The pharmacology is genuine; the evidence is thin on both sides, the supply is unverifiable, and the harms that are documented fall squarely on the systems a longevity-focused person is trying to protect.

Top - Benefits - Risks - Protocol

Melanotan II for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Increased Skin Pigmentation Without Ultraviolet Exposure

Initiation of Penile Erection in Men With Erectile Dysfunction

Medium 🟩 🟩

Increased Sexual Desire

Low 🟩

Reduced Appetite and Food Intake

Photoprotection From Increased Eumelanin ⚠️ Conflicted

Speculative 🟨

Improved Insulin Sensitivity and Metabolic Control

Neuroprotective and Cognitive Effects

Repigmentation in Vitiligo

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Vomiting

Unwanted Spontaneous Erections With Stretching and Yawning

Somnolence and Fatigue

Darkening of Existing Moles and Eruptive New Moles

Adulterated, Underdosed and Contaminated Product

Medium 🟥 🟥

Melanoma ⚠️ Conflicted

Blood Pressure and Heart Rate Elevation

Facial Flushing, Headache, Injection-Site Reactions and Sebaceous Effects

Priapism

Low 🟥

Rhabdomyolysis and Acute Kidney Injury

Renal Infarction

Posterior Reversible Encephalopathy Syndrome

Blood-Borne Infection From Injection Practice

Melanonychia and Nail Pigmentation

Speculative 🟨

Mucosal and Ocular Pigmentary Change

Long-Term Cardiovascular and Renal Remodeling

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion